Spravato (Intranasal esKetamine)
The FDA approved Spravato for use in treatment resistant depression in conjunction with an antidepressant in March of 2019.
The availability of Spravato may prove to be a godsend for individuals who are not able to afford ketamine infusion treatments – which are often not covered by insurance plans due to not being FDA approved for the purposes of treating depression or other psychiatric disorders.
What Is Spravato?
Spravato is a nasal spray that delivers esKetamine (a chemically related cousin to ketamine) into the body for the purpose of treating depression along with antidepressants.
Spravato may be covered by your insurance, alleviating any financial concerns you have about pursuing treatment for your depression. Every insurance plan is different and we offer a variety of options – including interest free financing – to make treatment as accessible as possible for those seeking a better way forward.